Quantcast

Latest Thrombocytopenia Stories

2008-09-15 15:00:09

WOODCLIFF LAKE, N.J., Sept. 15 /PRNewswire/ -- Eisai Inc. announced today its support of the Acting Surgeon General's Call to Action on venous thromboembolism (VTE), a serious and potentially life-threatening condition that includes deep vein thrombosis (DVT) and pulmonary embolism (PE). The Call to Action urges all Americans to learn about and prevent these treatable conditions. The announcement was made today during the annual meeting of the Venous Disease Coalition (VDC), an alliance of...

2008-09-15 09:00:58

Cleveland BioLabs, a drug discovery and development company, has received a $774,183 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic damage from radiation exposure. The grant program, medical countermeasures to enhance platelet regeneration and increase survival following radiation exposure, is funded through the Project BioShield Act...

2008-09-12 09:00:51

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has been awarded a $774,183 grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic (blood/bone marrow) damage from radiation exposure. The grant program, Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure, is...

2008-08-25 12:01:19

Amgen has announced that the FDA has approved Nplate, the first and only platelet producer for the treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura. According to the company, Nplate, the first FDA-approved peptibody protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of this chronic disease. The FDA approval of Nplate was based on efficacy and safety...

2008-08-25 09:00:26

The U.S. Food and Drug Administration says it has approved Nplate (romiplostim), the first product that directly stimulates bone marrow platelet production. The FDA said the new drug will be used to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding. The condition, which usually develops in adults, is known as chronic immune thrombocytopenic purpura, or ITP, a disease that results in a low number of platelets, the blood components that help...

2008-08-22 15:00:51

Amgen Inc. (NASDAQ: AMGN) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nplate(TM) (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate, the first FDA-approved peptibody protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of...

2008-08-22 03:00:10

By Fareed, J Iqbal, O; Cunanan, J; Demir, M; Wahi, R; Clarke, M; Adiguzel, C; Bick, R The conventional management of thrombotic and cardiovascular disorders is based on the use of heparin, oral anticoagulants and aspirin. Despite progress in the sciences, these drugs still remain a challenge and mystery. The development of low molecular weight heparins (LMWHS) and the synthesis of heparinomimetics represent a refined use of heparin. Additional drugs will continue to develop. However, none...

2008-08-21 09:00:22

Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes (MDS). This expanded indication supplements the 2004 FDA authorization of VIDAZA as the first therapy approved in the U.S. for the treatment of patients with all five French American British (FAB) subtypes of MDS. VIDAZA is also the...

2008-07-21 08:45:08

Hadasit Bio-Holdings, (HBL) a subsidiary of Hadasit (the technology transfer company of the Hadassah - Hebrew University Medical Center), which is traded on the Tel Aviv Stock Exchange under the symbol HDST, announced today that one of its portfolio companies, Verto (in which it has a 75% stake), has successfully completed a human clinical trial of a device for treating patients who suffer from systemic lupus erythematosus. The goals of the trial at the Hadassah Medical Center in Ein...

2008-07-17 12:01:18

Symphogen and Biovitrum have announced the recruitment of the first patient into a Phase II clinical trial, initiated in June 2008 to evaluate the safety and efficacy, and explore the dose range of Sym001 in idiopathic thrombocytopenic purpura patients. Up to 55 RhD-positive adult non-splenectomized patients with idiopathic thrombocytopenic purpura (ITP) will be enrolled in this first exploratory open label safety, efficacy and dose-finding trial. The study objective is to evaluate the...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related